BRÈVE

sur Biotest AG (isin : DE0005227201)

Biotest AG Prepares Yimmugo Launch in the USA, Secures Strategic Deal with Kedrion

Graphique de l'évolution du cours de l'action Biotest AG (EBR:BIO).

Biotest AG announces the upcoming launch of its immunoglobulin product, Yimmugo®, in the U.S. The framework for a billion-dollar distribution agreement with Kedrion has been established following FDA approval on June 13, 2024. The production of launch quantities has begun, and shipments to the U.S. are expected in Q4 2024, with market entry planned for Q1 2025.

The agreement is anticipated to generate over $1 billion in revenue for Biotest during its seven-year term. Yimmugo® is the first of several new proteins from Biotest, with others like fibrinogen and trimodulin also in late-stage development. CEO Peter Janssen expressed confidence in the commercial success of Yimmugo® in the U.S. market.

Yimmugo® will be the first drug manufactured using Biotest's innovative "Next Level" facility process. This collaboration spotlights Kedrion’s experience and Biotest's commitment to expanding patient access to immunoglobulin therapies in the U.S.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Biotest AG